邻苯二甲酸二戊酯(DPP)标准品
| EC | EINECS 205-017-9 |
| MDL | MFCD00041934 |
| 描述 | 密度：1.025?g/mL |
| 别名 | dipentyl phthalate;二戊基-1,2-苯二甲酸酯;邻酞酸二戊酯;邻酞酸二正戊酯;1,2-苯二甲酸二戊酯;DPP; |
| 英文名称 | Di-n-pentyl Phthalate |
| CAS | 131-18-0 |
| 分子式 | C18H26O4 |
| 分子量 | 306.4 |
| 储存条件 | RT |
| 单位 | 瓶 |
| SMILES | CCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCC |
| 规格 | 100mg |
苯甲酸阿格列汀
| EC | EINECS 691-730-4 |
| MDL | MFCD00064836 |
| 描述 | 是高活性DPP-4抑制剂。 |
| 别名 | SYR-322 |
| 英文名称 | Alogliptin Benzoate |
| CAS | 850649-62-6 |
| 分子式 | C18H21N5O2·C7H6O2 |
| 分子量 | 461.51 |
| 纯度 | ≥98% |
| 单位 | 瓶 |
| 生物活性 | Alogliptin benzoate是一种有效的，选择性的DPP-4抑制剂。[1] |
| In Vivo | We thus evaluated the chronic effects of the DPP-4 inhibitor alogliptin benzoate (formerly SYR-322) on metabolic control and beta-cell function in obese diabetic ob/ob mice. Alogliptin (0.002%, 0.01%, or 0.03%) was administered in the diet to ob/ob mice for 2 days to determine effects on plasma DPP-4 activity and active GLP-1 levels and for 4 weeks to determine chronic effects on metabolic control and beta-cell function. After 2 days, alogliptin dose-dependently inhibited DPP-4 activity by 28-82% and increased active GLP-1 by 3.2-6.4-fold. After 4 weeks, alogliptin dose-dependently decreased glycosylated hemoglobin by 0.4-0.9%, plasma glucose by 7-28% and plasma triglycerides by 24-51%, increased plasma insulin by 1.5-2.0-fold, and decreased plasma glucagon by 23-26%, with neutral effects on body weight and food consumption. Importantly, alogliptin also increased pancreatic insulin content up to 2.5-fold, and induced intense insulin staining of islets, suggestive of improved beta-cell function. In conclusion, chronic treatment with alogliptin improved glycemic control, decreased triglycerides, and improved beta-cell function in ob/ob mice, and may exhibit similar effects in patients with type 2 diabetes.[1] |
| SMILES | O=C(C=C(N1C[C@H](N)CCC1)N(C2=O)CC3=C(C#N)C=CC=C3)N2C.O=C(O)C4=CC=CC=C4 |
| 靶点 | Dipeptidyl Peptidase（DPP-4） |
| 数据来源文献 | [1]. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32. |
| 规格 | 5mg 10mg 25mg |
是一种有效的，选择性的DPP-4抑制剂。